We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current PRM market cap is 8.97M. The company's latest EPS is GBP -0.0115 and P/E is -2.60.
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Revenue | 4.75M | 5.13M | 7.78M | 5.03M | 4.89M |
| Operating Income | 567k | 517k | 1.49M | -1.47M | -2.27M |
| Net Income | 295k | 72k | 1.33M | -2.44M | -3.41M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Assets | 9.09M | 10.05M | 12.43M | 11.46M | 9.21M |
| Total Liabilities | 12.45M | 12.82M | 13.28M | 14.52M | 15.72M |
| Total Equity | -3.36M | -2.78M | -843k | -3.07M | -6.52M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Operating | 1.58M | 793k | 2.14M | -481k | -826k |
| Investing | -13k | -204k | -319k | -424k | -224k |
| Financing | -146k | -400k | -209k | -1.06M | 151k |
| Market Cap | 8.97M |
| Price to Earnings Ratio | -2.60 |
| Price to Sales Ratio | 1.8 |
| Price to Cash Ratio | 7.87 |
| Price to Book Ratio | -1.35 |
| Dividend Yield | - |
| Shares Outstanding | 295.18M |
| Average Volume (1 week) | 366.68k |
| Average Volume (1 Month) | 142.28k |
| 52 Week Change | -22.25% |
| 52 Week High | 5.40 |
| 52 Week Low | 2.30 |
| Spread (Intraday) | 0.88 (25.29%) |
| Company Name | Proteome Sciences Plc |
| Address |
coveham house surrey KT11 3EP |
| Website | https://www.proteomics.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
